Theratechnologies Inc. (NASDAQ:THTX – Get Rating) – Investment analysts at Cantor Fitzgerald cut their FY2023 earnings per share (EPS) estimates for Theratechnologies in a research note issued on Monday, January 9th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings of ($0.33) per share for the year, down from their previous forecast of ($0.19). Cantor Fitzgerald has a "Overweight" rating and a $9.00 price target on the stock. The consensus estimate for Theratechnologies' current full-year earnings is ($0.47) per share.

THTX has been the topic of several other research reports. Jonestrading initiated coverage on Theratechnologies in a research report on Wednesday, November 30th. They set a "buy" rating on the stock. Leede Jones Gab raised Theratechnologies from a "hold" rating to a "speculative buy" rating in a research report on Thursday, January 5th.

Theratechnologies Stock Down 8.0 %

Theratechnologies (NASDAQ:THTX – Get Rating) last posted its earnings results on Thursday, October 13th. The company reported ($0.08) earnings per share for the quarter. The business had revenue of $20.81 million for the quarter. Theratechnologies had a negative return on equity of 474.37% and a negative net margin of 63.59%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Atria Wealth Solutions Inc. acquired a new position in shares of Theratechnologies in the second quarter valued at approximately $33,000. HighTower Advisors LLC acquired a new position in shares of Theratechnologies in the first quarter valued at approximately $34,000. Range Financial Group LLC acquired a new position in shares of Theratechnologies in the first quarter valued at approximately $35,000. Virtu Financial LLC acquired a new position in shares of Theratechnologies in the first quarter valued at approximately $36,000. Finally, Second Half Financial Partners LLC acquired a new position in shares of Theratechnologies in the second quarter valued at approximately $40,000. Institutional investors and hedge funds own 33.22% of the company's stock.

Theratechnologies Company Profile

(Get Rating)

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients.

Featured Articles

• Get a free copy of the StockNews.com research report on Theratechnologies (THTX)
• Optimism About Global Demand For Metals Boosts BHP, Other Miners
• Exxon Mobil Expects Earnings and Cash Flow to Grow
• Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
• Is The Great Alibaba Recovery About To Begin?
• KB Home, Another Reason To Shed Home Building Stocks

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.